Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Random

Display 15 Products per page

Talzenna
Read More
Talzenna (talazoparib; Pfizer) is a small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the activity of PARP, an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events, by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death.
February 26, 2020
Find out more
Rebif
Read More
Originally developed by Merck KGaA, Rebif was first launched in the EU in 1998, followed by launch in the US in March 2002.
November 24, 2017
Find out more
Rytary
Read More
Rytary (Impax Laboratories) is a novel oral capsule formulation of carbidopa and levodopa that contains both an immediate-release and a sustained-release levodopa component.
June 21, 2018
Find out more
Tasigna
Read More
Tasigna (nilotinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor. In Philadelphia chromosome-positive chronic myeloid leukemia, the BCR-ABL protein activates a number of cell cycle-controlling proteins and enzymes, speeding up cell division.
December 7, 2017
Find out more
Opdivo
Read More
Opdivo is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.
September 9, 2019
Find out more
Company Analysis: Alexion

$3,000.00

PharmaVitae explores Alexion’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Gazyva
Read More
Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope of the CD20 antigen.
January 31, 2019
Find out more
U.S. Markets for General and Pelvic Endoscopic Surgery Products

$4,750.00

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, surgical procedure volumes, competitors, and opportunities in the U.S. General and Pelvic Endoscopic Surgery Products Market.
September 22, 2016
Find out more
Effient
Read More
An oral antiplatelet agent, Effient is a pro-drug which is converted to its active metabolite after
metabolism by cytochrome P450 enzymes.
April 14, 2016
Find out more
US Neurointerventional Devices Market, September 2016

$4,750.00

Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain.
September 21, 2016
Find out more
Datamonitor Healthcare Multiple Myeloma KOL Interview – UK

$599.00

This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need.
January 18, 2019
Find out more
NovoSeven
Read More
NovoSeven is a recombinant factor VIIa (rfVIIa) product marketed by Novo Nordisk.
May 4, 2018
Find out more
Pulmozyme
Read More
Developed by Genentech, Pulmozyme is a recombinant form of human deoxyribonuclease I produced by genetically engineered Chinese hamster ovary cells
September 3, 2018
Find out more
Invanz
Read More
Invanz (ertapenem; Merck & Co) is a carbapenem antibacterial agent that inhibits bacterial cell wall synthesis through binding to penicillin-binding proteins. The drug inhibits the crosslinking of…
June 19, 2015
Find out more
Early Access to Medicines in the US and Europe

$2,995.00

Faced with pressure from stakeholders – particularly patients – governments, regulators, and some countries have introduced new options and/or processes to speed up access to medicines. This includes access before marketing authorization, and speeding up the marketing authorization, or less often, the health technology assessment processes.

July 15, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *